Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings.
OBJECTIVE
Recently, we described an inverse association between cranberry supplementation and serum prostate specific antigen (PSA) in patients with negative biopsy for prostate cancer (PCa) and chronic nonbacterial prostatitis. This double blind placebo controlled study evaluates the effects of cranberry consumption on PSA values and other markers in men with PCa before radical prostatectomy.


METHODS
Prior to surgery, 64 patients with prostate cancer were randomized to a cranberry or placebo group. The cranberry group (n=32) received a mean 30 days of 1500 mg cranberry fruit powder. The control group (n=32) took a similar amount of placebo. Selected blood/urine markers as well as free and total phenolics in urine were measured at baseline and on the day of surgery in both groups. Prostate tissue markers were evaluated after surgery.


RESULTS
The serum PSA significantly decreased by 22.5% in the cranberry arm (n=31, P<0.05). A trend to down-regulation of urinary beta-microseminoprotein (MSMB) and serum gamma-glutamyltranspeptidase, as well as upregulation of IGF-1 was found after cranberry supplementation. There were no changes in prostate tissue markers or, composition and concentration of phenolics in urine.


CONCLUSIONS
Daily consumption of a powdered cranberry fruit lowered serum PSA in patients with prostate cancer. The whole fruit contains constituents that may regulate the expression of androgen-responsive genes.
Department of Urology, University Hospital Olomouc, Czech Republic.
Vladimir
V
Student
Department of Urology, University Hospital Olomouc, Czech Republic.
Ales
A
Vidlar
Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.|Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Jan
J
Bouchal
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Jana
J
Vrbkova
Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.|Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Zdenek
Z
Kolar
Department of Urology, University Hospital Olomouc, Czech Republic.
Milan
M
Kral
Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Pavel
P
Kosina
Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Jitka
J
Vostalova
D000230:Adenocarcinoma / Q000097:blood / Q000178:diet therapy* / Q000652:urine; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D019587:Dietary Supplements; D004311:Double-Blind Method; D015536:Down-Regulation; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology; D011300:Preoperative Care; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000178:diet therapy* / Q000652:urine; D016896:Treatment Outcome; D029799:Vaccinium macrocarpon
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
PSA; Vaccinium macrocarpon; adenocarcinoma; cancer markers; randomized controlled trial; urinary metabolites.